Algernon NeuroScience, a subsidiary of Algernon Pharmaceutic Algernon NeuroScience, a subsidiary of Algernon Pharmaceuticals, has begun a Phase 1 clinical stroke study of DMT in the Netherlands, using a single-escalating dose design to determine a safe, non-psychedelic dose.
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-subsidiary-algernon-neuroscience-230000040.html